Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges.
Diego Luigi CortinovisAlessandro LeonettiAlessandro MorabitoLuca SalaMarcello TiseoPublished in: Cancers (2024)
In resectable anaplastic lymphoma kinase-positive lung cancer, adjuvant alectinib represents the new standard of care and could soon be used in perioperative treatment.
Keyphrases
- early stage
- diffuse large b cell lymphoma
- protein kinase
- healthcare
- tyrosine kinase
- palliative care
- patients undergoing
- cardiac surgery
- sentinel lymph node
- quality improvement
- current status
- locally advanced
- squamous cell carcinoma
- radiation therapy
- combination therapy
- rectal cancer
- replacement therapy
- health insurance
- smoking cessation